

Product Name	: Infigratinib
Synonyms	: NVP-BGJ398; BGJ-398; BGJ398
Cat No.	: M16344
CAS Number	: 872511-34-7
Molecular Formula	: C ₂₆ H ₃₁ Cl ₂ N ₇ O ₃
Formula Weight	: 560.50
Chemical Name	: Urea, N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-[6-[[4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-N-methyl-
Description	Infigratinib (NVP-BGJ398, BGJ398) is a potent, selective pan-FGFR inhibitor with IC₅₀ of 0.9/1.0/1.4/60 nM for FGFR1/2/3/4, also shows high potency against mutant FGFR3-K650E with IC₅₀ of 4.9 nM; inhibits the proliferation of the FGFR1-, FGFR2-, and FGFR3-dependent BaF3 cells with IC₅₀ of low nanomolar range; shows significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3, significantly inhibits the growth of FGFR2-mutated endometrial cancer xenograft models, also ameliorates FGF23-mediated hypophosphatemic rickets in mouse models. Blood Cancer Phase 2 Clinical
Pathway	: Angiogenesis
Target	: FGFR
Receptor	: FGFR1; FGFR2; FGFR3; FGFR3(K650E); FGFR4
Solubility	: DMSO: 27 mg/mL
SMILES	: <chem>CCN1CCN(CC1)C1=CC=C(C(=NC2=CC(=NC=N2)N(C)C(=O)NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C=C1</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Guagnano V, et al. J Med Chem. 2011 Oct 27;54(20):7066-83. | 2. Guagnano V, et al. Cancer Discov. 2012 Dec;2(12):1118-33. | 3. Konecny GE, et al. Mol Cancer Ther. 2013 May;12(5):632-42.